Skip to content
DataLookout
Menu

NCT07946783

A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria changed
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of adverse events
Timeframe: Day 1 to Day 21

Secondary (4)

ZL65 Pharmacokinetics (PK):Cmax
ZL65 Pharmacokinetics (PK):Tmax
ZL65 Pharmacokinetics (PK):AUC0-t
ZL65 Pharmacokinetics (PK):t1/2

Arms and interventions

Single-ascending Dose (SAD) study and Food Effect (FE) studyExperimental
Multiple-ascending Doses (MAD) studyExperimental
Obesity with cardiovascular risk studyExperimental

Drugs: Single-ascending Dose (SAD) study and Food Effect (FE) study, Multiple-ascending Doses (MAD) study, Obesity with cardiovascular risk study

Sites

1 site in 1 country

  • Nucleus Network Pty Ltd Commercial RoadMelbourne, Australia